Comparison of Lucentic (Ranibizumab) and Ozurdex (Dexamethasone) for the treatment of patients with visual impairment due to macular edema following branch retinal vein occlusion

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-001019-30

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is to show that ranibizumab (administered in an individualized treatment regimen) has superior efficacy and safety compared to Dexamethasone implant (Ozurdex®) over a 6 months period


Critère d'inclusion

  • Visual Impairment due to macular oedema following branch retinal vein occlusion (BRVO)